Donald J. D'Amico, MD
Show Description +
Donald J. D'Amico, MD, presents the 18-month data of the phase 2/3 GATHER1 trial, which evaluated the monthly intravitreal injection of the novel C5 inhibitor avacincaptad pegol (Zimura, Iveric bio) for the treatment of geographic atrophy associated with AMD.
Posted: 11/05/2020
Donald J. D'Amico, MD
Donald J. D'Amico, MD, presents the 18-month data of the phase 2/3 GATHER1 trial, which evaluated the monthly intravitreal injection of the novel C5 inhibitor avacincaptad pegol (Zimura, Iveric bio) for the treatment of geographic atrophy associated with AMD.
Posted: 11/05/2020
Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of AAO: 2020.
Please log in to leave a comment.